Proteon Pharmaceuticals is glad to announce the latest findings from our recent studies: “A Rapid and Inexpensive PCR Test for Mastitis Diagnosis Based on NGS Data “. This new molecular test is a significant step forward in detecting mastitis, offering innovative eco-friendly solutions.
The full article, published in the international Pathogens journal online is available here.
Highlights from the article:
- Mastitis is an inflammation of the mammary gland, typically caused by bacterial infection.
- It is a common udder infection in dairy cows which can significantly impact dairy production, leading to economic losses due to reduced milk yield and compromised milk quality. Accurate identification of the pathogens responsible for mastitis is crucial for effective treatment.
![](https://www.proteonpharma.com/wp-content/uploads/2024/05/shutterstock_2402282967-300x127.jpg)
- The study aimed to develop a quick, accurate, and affordable way to identify the main pathogens causing mastitis. This research hopes to improve treatment and reduce costs for dairy farms.
- Our researchers have developed a new test, called a multiplex PCR test. They targeted four key pathogens, such as Streptococcus agalactiae or Streptococcus dysgalactiae, ensuring efficiency and relying on outcomes from next-generation sequencing (NGS).
- The multiplex PCR test was thoroughly ecaluated on 100 strains, including those from the Polish Collection of Microorganisms (PCM) and veterinary samples.
- The outcomes were very encouraging. Our test accurately identified the mastitis pathogens. This molecular tool has the potential to significantly improve the fight against mastitis on dairy farms worldwide.
With this groundbreaking test, Proteon Pharmaceuticals aims to provide dairy farmers with a powerful new tool to combat mastitis more effectively. By making pathogen detection faster, cheaper, and more accurate, we hope to enhance milk quality, benefiting farmers globally.
Researchers & authors: A. Kajdanek (Proteon Pharmaceuticals), M. Kluska, R. Matusiak (Proteon Pharmaceuticals), J. Kazimierczak (Proteon Pharmaceuticals), and J. Dastych (Proteon Pharmaceuticals).